Associated Papers
Identification of t(X;1)(q28;q21) generating a novel GATAD2B::MTCP1 gene fusion in CMML and its persistence during progression to AML.
Liu YZ et al.
Hematology (amsterdam, Netherlands), 2025
Human HDAC6 senses valine abundancy to regulate DNA damage.
Jin J et al.
Nature, 2025
TET2 Suppresses VHL Deficiency-Driven Clear Cell Renal Cell Carcinoma by Inhibiting HIF Signaling.
Zhang X et al.
Cancer Research, 2022
Linking the KIR phenotype with STAT3 and TET2 mutations to identify chronic lymphoproliferative disorders of NK cells.
Pastoret C et al.
Blood, 2021
Evaluation of allelic strength of human TET2 mutations and cooperation between Tet2 knockdown and oncogenic Nras mutation.
Chang YI et al.
British Journal of Haematology, 2014
Clinical and biological impact of TET2 mutations and expression in younger adult AML patients treated within the EORTC/GIMEMA AML-12 clinical trial.
Aslanyan MG et al.
Annals of Hematology, 2014
Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2.
Ko M et al.
Nature, 2010
21057493 (PubMed )
Supplement: NIHMS247005-supplement-3.pdf
Acquired mutations in TET2 are common in myelodysplastic syndromes.
Langemeijer SM et al.
Nature Genetics, 2009
Select a paper to view details